Vivos Therapeutics, Inc. (VVOS) stock
VVOSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$0.10+0.00 (+2.40%)
Close on Nov 13, 2026Market cap $1.97MP/E –Yield –
Vivos Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Vivos Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$20.77M. For fiscal 2025 it was -$18.59M. The highest annual figure on record is -$9.83M in fiscal 2019.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$18.59M | – |
| FY2024 | Dec 31, 2024 | -$10.59M | – |
| FY2023 | Dec 31, 2023 | -$16.68M | – |
| FY2022 | Dec 31, 2022 | -$24.36M | – |
| FY2021 | Dec 31, 2021 | -$19.65M | – |
| FY2020 | Dec 31, 2020 | -$11.32M | – |
| FY2019 | Dec 31, 2019 | -$9.83M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$4.32M | – |
| Q1 FY2026 | Mar 31, 2026 | -$6.16M | – |
| Q4 FY2025 | Dec 31, 2025 | -$5.94M | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.35M | – |
| Q2 FY2025 | Jun 30, 2025 | -$4.56M | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.74M | – |
| Q4 FY2024 | Dec 31, 2024 | -$2.66M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.50M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.79M | – |
| Q1 FY2024 | Mar 31, 2024 | -$3.64M | – |
| Q4 FY2023 | Dec 31, 2023 | -$3.98M | – |
| Q3 FY2023 | Sep 30, 2023 | -$3.49M | – |
| Q2 FY2023 | Jun 30, 2023 | -$4.37M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.83M | – |
| Q4 FY2022 | Dec 31, 2022 | -$5.89M | – |
| Q3 FY2022 | Sep 30, 2022 | -$5.23M | – |
| Q2 FY2022 | Jun 30, 2022 | -$6.80M | – |
| Q1 FY2022 | Mar 31, 2022 | -$6.60M | – |
| Q4 FY2021 | Dec 31, 2021 | -$7.24M | – |
| Q3 FY2021 | Sep 30, 2021 | -$5.31M | – |
| Q2 FY2021 | Jun 30, 2021 | -$3.87M | – |
| Q1 FY2021 | Mar 31, 2021 | -$3.23M | – |
| Q4 FY2020 | Dec 31, 2020 | -$6.07M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.64M | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.24M | – |
| Q1 FY2020 | Mar 31, 2020 | -$2.38M | – |
See a number that looks wrong?